Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
British Journal of Haematology|March 5, 2019
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccineMyrna R Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, et al.
Blood|October 24, 2002
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomePaul G Richardson, Carol Murakami, Zhezhen Jin, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
Leukemia|June 28, 2018
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomasEleni Anastasiadou, Dina Stroopinsky, Stella Alimperti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
Haematologica|February 4, 2021
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia modelDina Stroopinsky, Jessica Liegel, Manoj Bhasin, et al.
Blood|April 14, 2016
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host diseaseJohn Koreth, Haesook T Kim, Kyle T Jones, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
British Journal of Haematology|January 21, 2017
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1Michal Bar-Natan, Dina Stroopinsky, Katarina Luptakova, et al.
British Journal of Haematology|March 5, 2019
Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccineMyrna R Nahas, Dina Stroopinsky, Jacalyn Rosenblatt, et al.
Blood|October 24, 2002
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomePaul G Richardson, Carol Murakami, Zhezhen Jin, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
Leukemia|June 28, 2018
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomasEleni Anastasiadou, Dina Stroopinsky, Stella Alimperti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I TrialStefan Faderl, Meir Wetzler, David Rizzieri, et al.
Haematologica|February 4, 2021
Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia modelDina Stroopinsky, Jessica Liegel, Manoj Bhasin, et al.
Blood|April 14, 2016
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host diseaseJohn Koreth, Haesook T Kim, Kyle T Jones, et al.
Pageof 12